Comparative evaluation of three clinical decision support systems: prospective screening for medication errors in 100 medical inpatients by Fritz, Daniela et al.
PHARMACOEPIDEMIOLOGYAND PRESCRIPTION
Comparative evaluation of three clinical decision support
systems: prospective screening for medication errors in 100
medical inpatients
Daniela Fritz & Alessandro Ceschi & Ivanka Curkovic &
Martin Huber & Marco Egbring &
Gerd A. Kullak-Ublick & Stefan Russmann
Received: 27 October 2011 /Accepted: 1 February 2012 /Published online: 29 February 2012
# Springer-Verlag 2012
Abstract
Purpose Clinical decision support systems (CDSS) are pro-
moted as powerful screening tools to improve pharmaco-
therapy. The aim of our study was to evaluate the potential
contribution of CDSS to patient management in clinical
practice.
Methods We prospectively analyzed the pharmacotherapy
of 100 medical inpatients through the parallel use of three
CDSS, namely, Pharmavista, DrugReax, and TheraOpt. Af-
ter expert discussion that also considered all patient-specific
clinical information, we selected apparently relevant alerts,
issued suitable recommendations to physicians, and recorded
subsequent prescription changes.
Results For 100 patients with a median of eight concomitant
drugs, Pharmavista, DrugReax, and TheraOpt generated a
total of 53, 362, and 328 interaction alerts, respectively.
Among those we identified and forwarded 33 clinically
relevant alerts to the attending physician, resulting in 19
prescription changes. Four adverse drug events were associ-
ated with interactions. The proportion of clinically relevant
alerts among all alerts (positive predictive value) was 5.7, 8.0,
and 7.6%, and the sensitivity to detect all 33 relevant alerts
was 9.1, 87.9, and 75.8% for Pharmavista, DrugReax and
TheraOpt, respectively. TheraOpt recommended 31 dose
adjustments, of which we considered 11 to be relevant; three
of these were followed by dose reductions.
Conclusions CDSS are valuable screening tools for med-
ication errors, but only a small fraction of their alerts
appear relevant in individual patients. In order to avoid
overalerting CDSS should use patient-specific informa-
tion and management-oriented classifications. Comprehen-
sive information should be displayed on-demand, whereas a
limited number of computer-triggered alerts that have man-
agement implications in the majority of affected patients
should be based on locally customized and supported
algorithms.
Keywords Clinical decision support software . Dose
adjustment . Drug interactions
Introduction
Adverse drug events (ADE), which are an important cause
of morbidity and mortality and result in increased healthcare
costs, are a challenging problem in clinical patient care
[1–7]. Drug interactions and dosing errors leading to ADE
are of special interest because they represent preventable
medication errors that are suitable targets for highly efficient
automated interventions through computerized physician
order entry (CPOE) with clinical decision support systems
(CDSS). The efficacy of CDSS to modify physicians’ be-
havior in clinical practice and thereby to reduce medication
errors and improve monitoring of pharmacotherapy has
been well established, whereas their efficacy to reduce
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ADE and costs is less well documented and needs further
investigation [8–15]. In addition, few studies have com-
pared the performance of different CDSS, and these were
usually not conducted under real-life conditions. The clas-
sification and grading of medication errors is a complex and
challenging task, and previous studies have reported major
disagreements in the assessment of drug interactions be-
tween different CDSS [16–18] and specialists [19]. Further-
more, general assessments may not apply well to specific
patients where prescribing clinicians also use additional
complex non-standardized clinical information for manage-
ment decisions [20, 21]. In general, it appears that most
CDSS have a high sensitivity to detect drug interactions at
the cost of low specificity to discriminate those interactions
that are clinically relevant. In combination with an insuffi-
cient consideration of patient-specific factors by CDSS, this
leads to indiscriminate overriding of alerts by prescribing
clinicians, which jeopardizes the efficacy of CDSS to im-
prove medication safety in clinical practice [22].
For our routine clinical pharmacology “safety ward
rounds”, we use several CDSS as an initial screening
tool to search for drug interactions and dosing errors in
hospitalized patients. However, given the limitations
mentioned above, after automated screening we also
access the electronic medical records of the respective
patients in order to evaluate the clinical relevance of
potential medication errors initially identified by the
CDSS. Only if we conclude that a potential medication
error is clinically relevant in the patient’s individual
clinical context do we alert the responsible physician
and discuss appropriate alternatives. Because there is a
need for systematic evaluations of the performance of
different CDSS in real-life clinical settings, we have
analyzed our experience with the use of different CDSS
in combination with clinical pharmacology expertise for
the identification and prevention of medication errors.
The results of this analysis are reported here.
Methods
Study design
We present a prospective naturalistic analysis that eval-
uated the performance of CDSS used as part of our
surveillance of pharmacotherapy at two general internal
medicine wards of a tertiary care university hospital.
Our surveillance has the aim to optimize the efficacy
and safety of pharmacotherapy. Because this study is a
systematic analysis of our established routine clinical
practice it was exempt from ethical approval. A sum-
mary of the procedures is presented in Fig. 1. The study
includes 100 consecutive patients for an evaluation of
all concomitantly prescribed drugs with a focus on
potential drug interactions. There were no formal exclu-
sion criteria. A formal power analysis was not applica-
ble in this descriptive pilot analysis, and the decision to
include 100 patients was based on pragmatic and some-
what arbitrary grounds. As our surveillance is performed
at certain days of the week and patients may also had
been transferred from other wards, the day of analysis
in relation to hospital admission varied. All concomi-
tantly prescribed drugs were simultaneously analyzed
with three different CDSS, i.e., Micromedex DRUG-
REAX, Atheso TheraOpt (which in the meantime has
been taken over by ID Berlin), and Pharmavista
[23–25]. Of note, Pharmavista did not allow the entry
of more than eight concomitantly used drugs at any one
time, and for patients using more than eight drugs an
interaction analysis could therefore not be performed
with Pharmavista. Automatically generated alerts from
all three CDSS were documented. Subsequent to receiv-
ing the automatically generated alerts, at least one junior
and one senior clinical pharmacologist from our depart-
ment discussed and evaluated the clinical relevance
of the alerts in the individual clinical context of each
patient. Alerts were defined as clinically relevant if we
considered a change of therapy to be necessary. For that
purpose we also accessed the hospital’s clinical infor-
mation system containing all electronic drug prescrip-
tions, medical reports, and laboratory results. We then
forwarded only those alerts that we presumed to be
clinically relevant to the attending physician, usually
by personal communication during ward rounds or over
the phone, and made an entry into the electronic patient
record. If appropriate, we also provided additional in-
formation and management recommendations, including
possible alternative therapies and monitoring. Thereafter,
we followed the electronic prescribing record for those
patients until hospital discharge in order to document
whether prescriptions had been changed in accordance with
our recommendations. We also specifically searched med-
ical reports and laboratory results for signs and symptoms of
ADE that may have resulted from prescriptions addressed in
the alerts.
Outcomes and data analysis
Primary outcomes of the study were the comparative num-
ber of alerts generated by each CDSS and the fractions
thereof that we considered to be clinically relevant and
therefore forwarded to the attending physicians. In order to
compare the performance of the three CDSS we calculated
their sensitivity and positive predictive value (PPV) in terms
of their identification of clinically relevant drug interactions
as follows. Sensitivity 0 number of interactions among all
1210 Eur J Clin Pharmacol (2012) 68:1209–1219
interactions evaluated as clinically relevant identified by the
respective CDSS divided by all interactions evaluated as
clinically relevant identified by any CDSS or during expert
discussion; PPV 0 number of interactions identified by the
respective CDSS and evaluated as clinically relevant divid-
ed by the number of interactions identified by the respective
CDSS. We compared the sensitivity and PPV between dif-
ferent CDSS using the chi-square test.
Additional measures of interest included the number of
actual medication changes in response to those alerts that we
had forwarded to the attending physicians as well as strati-
fied analyses, such as by CDSS grading, and the description
of specific alerts and associated ADE. Data manage-
ment, analyses, and construction of figures were done
using STATA 11.2 for MacOS X (STATA Corp, College
Station, TX).
Results
Patient characteristics and drug use
Demographic and clinical characteristics of all 100 included
patients are presented in Table 1. The median age was
Fig. 1 Procedures. Overview
of the pharmacotherapy
evaluation process. CDSS
Clinical decision support
system
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59.3 years (range 23–86), and in 70 patients the pharmaco-
therapy was analyzed between days 2 and 9 after admission
(median and mean 5 and 6.5 days, respectively). Forty-four
patients had impaired renal function with a glomerular fil-
tration rate (GFR) of <60 ml/min, 11 had liver disease with a
CHILD score of ≥7, 23 had undergone organ transplantation
at any time in the past, and 25 patients had malignant
tumors.
Table 2 presents the most commonly prescribed drugs in
the study population. Overall, there were 892 prescriptions
in 100 patients. Based on drug classification, antibiotics
ranked as the most frequently prescribed drug class, ac-
counting for 110 prescriptions (12.3%) in 50 patients, fol-
lowed by heparins, proton pump inhibitors, diuretics, and
beta-blockers.
A histogram of the polypharmacy distribution is shown
in Fig. 2. The mean and median number of concomitant
substances prescribed to each patient was 8.9 and 8,
respectively.
Drug interactions
The correlation between polypharmacy and the mean num-
ber of identified interactions per patient by each CDSS is
shown in Fig. 3. As expected, based on the exponential
increase of possible combinations, increasing polypharmacy
was also associated with a pronounced increase of identified
interactions. Because Pharmavista can only analyze up to
eight concomitantly prescribed drugs, there are no results
from Pharmavista for patients receiving more than eight
drugs. Consequently, the overall number of interactions
identified by Pharmavista was much lower compared to
DrugReax or Theraopt (Pharmavista 53, DrugReax 362,
TheraOpt 328). As expected, for patients receiving up
to eight drugs, differences in the number of identified
interactions were smaller (Pharmavista 53, DrugReax 75,
TheraOpt 56). An overview of the identification of drug
interactions by each CDSS, including our subsequent expert
evaluation and implementation of the resulting recommen-
dations by the treating physicians, is provided in Table 3.
Among all interaction alerts generated by any CDSS, we
evaluated 33 interactions as clinically relevant in the indi-
vidual clinical context of the respective patients. Of note,
when a CDSS classified an alert as severe and we did not
forward this alert to the treating physician, the reason for our
decision was documented. For example, there were five
“severe” pharmacokinetic interaction alerts with cyclospor-
ine, but therapeutic drug monitoring indicated the appropri-
ate dose adjustment with concentrations in the therapeutic
range. Other examples include the combination of several
drugs that increase the risk of bleeding when there was an
evidence-based indication for this combination, or the com-
bination of several potassium-sparing drugs when potassium
concentrations were indeed normal and stable. The propor-
tion of generated alerts that we considered to be clinically
Table 1 Patient characteristics
Characteristics n
Total 100
Sex
Female 42
Male 58
Age category (years)
<50 20
50–59 32
60–69 19
70–79 17
≥80 12
Time of pharmacotherapy evaluation (days after admission)
0–1 16
2–4 33
5–9 37
≥10 14
Disease categoriesa
Gastroenterology and hepatology 25
Nephrology 24
Internal medicine 17
Cardiology 11
Angiology 6
Oncology 4
Pneumology 4
Endocrinology 3
Hematology 3
Infectiology 2
Immunology 1
Renal function (GFR, ml/min/1.73 m2)b
≥60 56
30–59 22
<30, no dialysis 11
Dialysis 11
Liver disease with CHILD score ≥7
Yes 11
No 89
Malignancy
Yes 25
No 75
Transplantation
Liver 2
Lung 5
Kidney 16
a Only one primary diagnosis per patient
bMost recent glomerular filtration rate (GFR) before pharmacotherapy
evaluation according to the MDRD-formula
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relevant (which corresponds to the PPV) was comparable
for the three CDSS, i.e., between 5.7 and 8% (p >0.1 for all
comparisons). The sensitivity to detect the 33 relevant inter-
actions was 87.9% for DrugReax, 75.8% for TheraOpt, and
9.1% for Pharmavista (p <0.001 for TheraOpt or DrugReax
vs. Pharmavista; p >0.1 for DrugReax vs. TheraOpt). Fur-
ther stratification by severity classification (Table 3) showed
(1) a poor correlation between CDSS severity class and our
evaluation of clinical significance for individual patients and
(2) that DrugReax assigned a higher proportion of its alerts
to a higher severity class than TheraOpt. A detailed descrip-
tion of all relevant interactions is presented in Table 4.
Amiodarone was involved in eight interactions, antimy-
cotics in seven, and statins and immunosuppressants in
six each. Pharmacokinetic and pharmacodynamic interaction
mechanisms were involved with an about equal frequency.
For 19 of the 33 forwarded alerts (57.6%), we observed a
subsequent prescription change that was in line with our
recommendations.
Dosing
TheraOpt is also able to identify dosing errors based on
recommended maximum doses for specific indications, gen-
der, age, and renal and liver function. We used this feature
for an evaluation of the appropriate dosing for all prescrip-
tions. TheraOpt recommended 31 dose adjustments, and we
found one additional dosing problem related to a decreased
first pass of metoprolol in cirrhosis. Among these 32 “dos-
ing problems,” we considered 11 as justified and forwarded
recommendations for prescription changes, which were fol-
lowed by changes in three cases (Table 5).
Adverse drug events
In four patients we detected adverse events that were possi-
bly related to the identified interaction or dosing issues. In
the first case, oral ciprofloxacin was combined with oral
calcium, and the patient developed cholecystitis and Escher-
ichia coli sepsis. Impaired absorption of ciprofloxacin may
have contributed to treatment failure, leading to prolonged
hospitalization in this case. In the second case, a patient
developed hypokalemia (2.9 mmol/l) under combined ther-
apy with hydrochlorothiazide, torasemide, and prednisone.
After medication change, the patient’s serum potassium
quickly normalized. The third patient concomitantly re-
ceived itraconazole capsules and pantoprazole. Proton pump
inhibitors are known to impair the bioavailability of itraco-
nazole capsules [26], and drug monitoring indeed showed
subtherapeutic itraconazole concentrations (0.2 mg/l; target
level is > 1 mg/l). The fourth patient had a transjugular
intrahepatic portosystemic shunt (TIPS) and received 6 mg
budesonide per day for autoimmune hepatitis with cirrhosis
stage Child B. This patient developed a thrombosis of
the TIPS. Elevated bioavailability of budesonide due to
Table 2 Prescription frequencies for different drug categories/classesa
Drug classes Number of
prescriptions
Number of patients
with prescriptions
n % n (0%)
Total 892 100 100
Antibiotics 110 12.3 50
Heparins 63 7.1 63
Proton pump inhibitors 60 6.7 60
Diuretics 52 5.8 40
Beta blockers 43 4.8 43
Immunosuppressants 40 4.5 23
HMG-CoA inhibitors 38 4.3 38
Antiplatelets 37 4.2 28
Corticosteroids systemic 34 3.8 34
ACE inhibitors 28 3.1 28
Vitamins 28 3.1 28
Antivirals 26 2.9 15
Calcium salts 22 2.5 22
Laxatives 22 2.5 18
Hormones 20 2.2 17
Calcium channel blockers 19 2.1 19
Antifungals 16 1.8 12
Potassium salts 16 1.8 16
Angiotensin renin blockers 14 1.6 14
Benzodiazepines and GABA
agonists
14 1.6 13
Oral anticoagulants 14 1.6 14
Insulins 13 1.5 9
Analgetics metamizole 11 1.2 11
Analgetics opioids 10 1.1 10
Analgetics paracetamol 9 1.0 9
Antidepressants 9 1.0 7
Antiemetics 9 1.0 8
Antiepileptics 9 1.0 7
Oral glucose lowering agents 9 1.0 7
Antiarrhythmics 8 0.9 7
Antiasthmatics 7 0.8 3
Magnesium salts 7 0.8 7
Neuroleptics 7 0.8 7
Antiparkinson drugs 4 0.5 2
Uricostatics 4 0.5 4
NSAIDs 2 0.2 2
Other 58 6.5 44
HMG-Co, 3-Hydroxy-3-methylglutaryl-coenzyme A; ACE, angioten-
sin converting enzyme; GABA, gamma-aminobutyric acid; NSAIDs,
nonsteroid anti-inflammatory drugs
a Data are presented as the number of prescriptions and number of
patients with such prescriptions for different drug categories
Eur J Clin Pharmacol (2012) 68:1209–1219 1213
portocaval shunting in association with portal vein throm-
bosis has been described [27], and elevated concentrations
may have contributed to TIPS thrombosis here.
Discussion
This study presents a systematic analysis of our experience
with three different CDSS used as screening tools for med-
ication errors in daily clinical routine.
First, our results provide information on the occurrence
of specific medication errors in the studied setting. Amio-
darone, antimycotics, cholesterol-lowering 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA)-reductase inhibi-
tors, and immunosuppressants were most frequently involved
in relevant interactions, underlining that any prescribing
physician should give particular attention to their interaction
profiles and routinely check for interactions when prescribing
these drugs. Of interest, a previous study using a different
CDSS in a different population of 84,607 psychiatric inpa-
tients also found amiodarone to have the highest intrinsic risk
of interactions [28]. We also found some cases in which there
was a need for dose adjustments. Most were related to renal
insufficiency and some also to cirrhosis and high age, but
there was no single drug frequently prescribed with an unad-
justed dose. Overall, a total of 22 medication changes follow-
ing our combined 44 recommendations relating to interactions
or dosing in 100 patients suggest that pharmacotherapy could
be improved in a considerable proportion and absolute num-
ber of hospitalized patients. Although our analysis was not
designed and powered to demonstrate a reduction in clinical
outcomes and costs, the detection of possible ADE in 4% of
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the population is in accordance with earlier reports [1–4].
Although ADE are relatively rare, an extrapolation of our
results to the whole patient population of a hospital would
yield a considerable absolute number of preventable ADE and
therefore supports the view that local efforts to introduce
preventive countermeasures should be increased.
Considering CDSS as such potentially appropriate coun-
termeasures, the results of our study provide important
insight into several areas of interest, i.e., the comparative
performance, the applicability, and the clinical relevance
and potential benefits of CDSS use in routine clinical prac-
tice. In contrast to the primarily intended use of CDSS by
prescribers and office pharmacists, a key feature of our
study is that we, as clinical pharmacologists, used CDSS
as a screening tool for medication errors, whereas the pre-
scribing physicians were not directly confronted with
CDSS-generated alerts. Instead, we made a preselection
of presumably clinically relevant alerts, based on both
patient-specific information and our clinical expertise, and
subsequently were able to enhance the automated alerts by
additional management recommendations. The rationale for
this approach is our own experience as well as an increasing
number of reports in the literature [22, 29–34] that have
identified overalerting as a major issue with currently avail-
able CDSS. Indeed, although most alerts could be consid-
ered as generally valid, for all three CDSS that we used
more than 90% of alerts appeared to be clinically irrelevant
when they were applied to the management of specific
patients. Therefore, also in our setting, forwarding all alerts
without selection would have most likely led to indiscrim-
inate overriding. Furthermore, our finding that many clini-
cally relevant interactions were classified as moderate or
even mild according to the classic “traffic light” grading
used by all three CDSS indicates that even filtering only
“severe” alerts would not be a reasonable solution. Indeed, a
previous study also reported that customization of CDSS by
common severity levels was not able to improve effective-
ness [32]. The more management-oriented Operational
Table 3 Identification and evaluation of drug interactionsa
Identification and evaluation of interactions PharmaVistab DrugReax TheraOpt
n % n % n %
All interactions 53 100 362 100 328 100
Evaluated as clinically relevant (PPVc) 3 5.7 29 8.0 25 7.6
Sensitivityd 9.1 87.9 75.8
Alert followed by prescription change 3 5.7 17 4.7 13 4.0
Adverse event associated with interaction 0 0 3 0.8 3 0.9
Mild interactions 36 100 23 100 213 100
Evaluated as clinically relevant (PPVc) 3 8.3 0 0 4 1.9
Sensitivityd 9.1 0 12.1
Alert followed by prescription change 3 8.3 – – 4 1.9
Adverse event associated with interaction 0 0 – – 0 0
Moderate interactions 17 100 248 100 104 100
Evaluated as clinically relevant (PPVc) 0 0 12 4.8 15 14.4
Sensitivityd 0 36.4 42.4
Alert followed by prescription change – – 5 2.0 5 4.8
Adverse event associated with interaction – – 3 1.2 3 2.9
Severe interactions 0 – 91 100 11 100
Evaluated as clinically relevant (PPVc) – – 17 18.7 6 54.5
Sensitivityd 0 51.5 18.2
Alert followed by prescription change – – 12 13.2 4 36.4
Adverse event associated with interaction – – 0 0 0 0
a Identification of drug interactions by CDSS and further expert evaluation according prescription changes and associated adverse events. Overall
results are presented first, followed by stratifications over the severity grading of interactions
b Pharmavista did not analyze pharmacotherapy if the number of concomitant drugs was >8
c Percentage value equals positive predictive value (PPV): PPV 0 (number of interactions identified by the respective CDSS and evaluated as
clinically relevant/number of interactions identified by the respective CDSS) × 100
d Sensitivity (%) 0 (number of interactions among all 33 interactions evaluated as clinically relevant identified by the respective CDSS/all 33
interactions identified by any source and evaluated as clinically relevant) × 100
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Classification of Drug Interactions (ORCA) has been
developed with this issue in mind [35], and recently
we proposed an extension of ORCA that also supports
the implementation of patient-specific information and
potential outcomes of drug interactions in CDSS algo-
rithms [28, 36, 37]. Currently ongoing studies that
evaluate CDSS based on such management-oriented classi-
fications will show whether they can make a relevant contri-
bution to the reduction of overalerting.
A comparison of the three CDSS in terms of their
sensitivity to detect clinically relevant interactions shows
that DrugReax and TheraOpt performed better than
Pharmavista. Interpretation of this result must certainly
take into account Pharmavista’s inability to analyze
more than eight drugs concomitantly, which applied to
42% of our medical in-patient population, and it may be
less of an issue in a pharmacy setting, where Pharma-
vista is frequently used. Nevertheless, our results indicate that
Table 4 Listing of all drug interactions that were identified by CDSS and evaluated as clinically relevant during expert discussiona
Interacting drugs CDSS detection and
severity gradingb
Potential adverse event Mechanismc Prescription change
PhVis DRx ThOpt
Amiodarone–simvastatin x 3 2 Myopathy PK No
Amiodarone–atorvastatin x 2 2 Myopathy PK Yes
Amiodarone–metronidazole x 3 x QT-prolongation PD Yes
Amiodarone–cotrimoxazole x 3 3 QT-prolongation PD Yes
Amiodarone–itraconazole x 3 x QT-prolongation PD Yes
Amiodarone–clarithromycin (n 02) x 3 3 QT-prolongation PD 2× yes
Amiodarone–ciprofloxacin x 3 x QT-prolongation PD Yes
Cyclosporine–simvastatin x 3 2 Myopathy PK Yes
Cyclosporine–pravastatin x 2 2 Myopathy PK No
Cyclosporine–morphine–loperamide x x x Increased levels of cyclosporine
and morphine
PK No
Tacrolimus–itraconazole x 3 2 Increased levels of tacrolimus PK No
Tacrolimus–clarithromycin x 2 2 Increased levels of both drugs PK No
Tacrolimus–metronidazol x 2 x Increased levels of tacrolimus PK No
Clarithromycin–domperidone–itraconazol x x 2 QT-prolongation PK Yes
Clarithromycin–cotrimoxazole (n 03) x 3 3 QT-prolongation PD 1× yes, 2× no
Cotrimoxazole–fluconazole x 3 x QT-prolongation PD 1
Ciprofloxacin–atorvastatin x 2 2 Myopathy PK No
Ciprofloxacin–calciumd (n 02) x 2 2 Decreased efficacy (BVe ↓) PK Yes/no
Itraconazole–ranitidine x 2 2 Decreased efficacy (BVe ↓) PK No
Itraconazol–omeprazole x 2 2 Decreased efficacy (BVe ↓) PK No
Itraconazole–pantoprazoled x 2 2 Decreased efficacy (BVe ↓) PK No
Pipamperone–trimipramine x 3 2 QT-prolongation PD No
Ursodeoxycholic acid–colestyramin 1 x 1 Decreased efficacy (BVe ↓) PK Yes
Daptomycin–pravastatin x x 2 Myopathy PD Yes
Torasemide–HCTZ–prednisoned x 2 1 Hypokalemia PD Yes
Ginkgo biloba–acetylsalicylic acid 1 3 1 Bleeding PD Yes
Ginkgo biloba–clopidogrel 1 2 1 Bleeding PD Yes
Clopidogrel–esomeprazole x 3 x Decreased clopidogrel efficacy PK Yes
Terlipressin–quetiapine x 3 x QT-prolongation PD Yes
a Twenty-nine distinct interactions occurring in 33 instances
b Key for severity grading: 1 0 mild, 2 0 moderate, 3 0 severe, x 0 not detected; PhVis, Pharmavista; DRx, DrugReax; ThOpt, Theraopt
c PK, Pharmacokinetic; PD, pharmacodynamic
d Associated with adverse event (see text)
e BV, Bioavailability, refers to the first drug of the listed combination
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it is quite a relevant limitation for a medical in-patient
population.
Among all of the interaction alerts that we considered as
relevant, 58% ultimately resulted in a prescription change.
This demonstrates that our preselection of alerts based on
patient-specific clinical information and our proposals of
management recommendations in combination with person-
al communication of the alerts were generally well received
by the attending physicians and able to overcome the major
problem of overriding drug safety alerts to a large part. For
the remaining 42% of alerts that were not followed by a
prescription change, clinicians may have either judged our
recommendations as not justified (which may or may not be
true), or indiscriminative overriding may have occurred.
Previous studies have identified the most frequent reasons
for drug safety alert overriding as: (1) the problem was
already known but clinically not important; (2) there were
no reasonable alternatives while the benefit was considered
to be greater than the risk; (3) the potential problem could be
managed by appropriate monitoring; (4) the dose had been
adjusted; (5) the patient had previously tolerated the medi-
cation [31, 32]. Similar reasons were brought forward when
we contacted the prescribers. We also realize that there are a
number of unavoidable limitations to our assessments, such
as the fact that in the absence of a gold standard for the
clinical relevance of potential medication errors, it is possi-
ble that we excluded some relevant alerts, oversaw addition-
al medication errors or, on the other hand, forwarded some
irrelevant alerts. However, we neither identified additional
ADE, nor does it appear likely that the combined sensitivity
of the three CDSS plus our manual review failed to identify
a relevant number of medication errors.
Regardless of the reason for overriding safety drug alerts
and the differences that we found between CDSS, the fact
that less than 10% of automated alerts were assessed as
relevant for individual patients forces us to rethink how
future CDSS can be effectively and efficiently applied for
the prevention of medications errors, ADE, and unnecessary
costs in clinical practice. Maximum sensitivity may be a
common priority in the development of CDSS, and much of
the content of such systems can be tracked down to the
safety information included in the manufacturer’s prescrib-
ing information where, also for legal reasons, comprehen-
siveness rather than clinical relevance is determinative. The
comprehensive and generally valid alerts and comments
from all three CDSS were certainly useful for screening
and learning purposes in our setting. However, eventually
CDSS must be integrated with CPOE and automatically
display alerts that have a high propensity of clinical rele-
vance. Indeed, approaches that target specific relevant prob-
lems of pharmacotherapy have demonstrated their efficacy
not only in modifying prescribing behavior but also in
improving clinical outcomes [38]. Therefore, we propose
that, on the one hand, the valuable comprehensive knowl-
edge from CDSS should be easily available (via “one click”)
to the prescriber, but only on an on-demand basis. On the
other hand, there should be a list with a limited number of
automatically computer-triggered alerts. Clinical pharma-
cologists can initially develop such a list and make a prese-
lection that focuses on clinical relevance and management
implications. Local retrospective systematic evaluations of
medication errors and ADE that occurred in the past can also
contribute to and help to justify the use of such a list [36,
37]. However, the list should also be reviewed and sup-
ported by local leading clinicians in order to enhance its
local acceptance. Furthermore, the importance of patient-
specific factors in our study suggests that alert algorithms
must also include as much laboratory and clinical informa-
tion as possible. Indeed, obtaining laboratory results as part
of intensified monitoring could also be part of clinical
actions recommended and surveyed by CDSS. This requires
interfaces that integrate CDSS with laboratory and clinical
information systems. For example, alert algorithms may
include current electrolyte results and QTc times from auto-
mated electrocardiogram readings. Although we did not use
CDSS with integration into CPOE and clinical information
systems in our setting, it is important to note that TheraOpt
and other currently available CDSS have indeed been
Table 5 Dosing recommenda-
tions initially identified by
TheraOpt and subsequently
evaluated as clinically relevant
GFR, Glomerular filtration rate
an 01 for all dosing errors with
the exception of zolpidem 10 mg
(n 02)
b Associated with adverse event
(see text)
Actual prescriptiona Dosing issue Prescription change
Zolpidem 10 mg >65 years standard dose 5 mg Yes/no
Chlortalidon Contraindicated in severe renal impairment Yes
Budesonideb In cirrhosis high first pass Yes
Hydrochlorothiazide Contraindicated in severe renal impairment No
Metformin Contraindicated in severe renal impairment No
Simvastatin 40 mg Maximum 10 mg if GFR <30 No
Metamizole 3 g Lower dose in renal impairment No
Pantoprazole 40 mg In cirrhosis, maximum 20 mg No
Clarithromycin 2× 250 mg Maximum 250 mg if GFR <30 No
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designed in this a way. However, if this approach is used for
all interactions of a highly sensitive CDSS, its complexity
and applicability will likely become uncontrollable and re-
sult once more in overriding of the drug safety alerts.
Conclusions
The studied CDSS are valuable screening tools for medica-
tion errors, but only a small fraction of all alerts are clini-
cally relevant in individual patients. Insufficient use of
patient-specific information in alert algorithms and lack of
local customization compromise their applicability and effi-
cacy in clinical practice. In addition, lack of scientific evi-
dence in complex individual patient care and common off-
label use remain major challenges for CDSS. We therefore
propose that CDSS should separate comprehensive on-
demand information from selected computer-triggered alerts
that must be locally supported, customized and frequently
updated, and have management implications in the majority
of patients where they are displayed. The initial setup plus
necessary ongoing evaluations and adjustments of such a
system requires expertise and additional resources. However,
compared to a standard CDSS without appropriate local pro-
motion and support, such an approach may not only be more
efficacious but also more efficient.
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